Technical Analysis for RDY - Dr. Reddy's Laboratories Ltd

Grade Last Price % Change Price Change
B 74.55 0.72% 0.53
RDY closed up 0.72 percent on Friday, April 26, 2024, on 88 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Up Flat Up

Date Alert Name Type % Chg
Crossed Above 50 DMA Bullish 0.00%
Calm After Storm Range Contraction 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
50 DMA Resistance Bearish 0.72%
Crossed Above 20 DMA Bullish 0.72%
MACD Bullish Signal Line Cross Bullish 0.72%
New Uptrend Bullish 0.72%
Pocket Pivot Bullish Swing Setup 0.72%
Gapped Up Strength 0.72%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 5 hours ago
Up 1% about 9 hours ago
Upper Bollinger Band Resistance about 9 hours ago
Rose Above Previous Day's High about 9 hours ago
Rose Above 50 DMA about 9 hours ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dr. Reddy's Laboratories Ltd Description

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company. It operates in three segments: Pharmaceutical services and Active Ingredients (PSAI), Global Generics, and Proprietary Products. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to biotech and pharmaceutical companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in the operation of biologics business. The Proprietary Products segment engages in the discovery and development of new chemical entities for subsequent commercialization and out-licensing. It offers new, synergistic combination, and technology formulations that modifies pharmacokinetics of existing medicines. This segment is also involved in the Company's specialty pharmaceuticals business that includes sales and marketing operations for in-licensed and co-developed dermatology. The company offers its products and services primarily in the areas of gastrointestinal, cardiovascular, pain management, and oncology therapies. It primarily operates in India, the United States, Russia and other countries of the former Soviet Union, Europe, and others. Dr. Reddy's Laboratories Limited was founded in 1984 and is headquartered in Hyderabad, India.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Pharmaceutical Pharmaceutical Products Gastrointestinal Dermatology Pain Management Active Pharmaceutical Ingredients Pharmacokinetics Chemical Entities Oncology Therapies Contract Research Services Pharmaceutical Industry In India Pharmaceutical Services Biotech And Pharmaceutical

Is RDY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 77.72
52 Week Low 52.332
Average Volume 180,676
200-Day Moving Average 69.67
50-Day Moving Average 74.19
20-Day Moving Average 72.55
10-Day Moving Average 71.92
Average True Range 1.09
RSI (14) 59.18
ADX 25.15
+DI 31.51
-DI 23.35
Chandelier Exit (Long, 3 ATRs) 71.53
Chandelier Exit (Short, 3 ATRs) 73.97
Upper Bollinger Bands 74.96
Lower Bollinger Band 70.14
Percent B (%b) 0.92
BandWidth 6.64
MACD Line -0.30
MACD Signal Line -0.59
MACD Histogram 0.2893
Fundamentals Value
Market Cap 12.41 Billion
Num Shares 167 Million
EPS 3.77
Price-to-Earnings (P/E) Ratio 19.77
Price-to-Sales 0.05
Price-to-Book 3.82
PEG Ratio 4.87
Dividend 40.00
Dividend Yield 53.66%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 75.36
Resistance 3 (R3) 75.35 75.06 75.23
Resistance 2 (R2) 75.06 74.86 75.07 75.18
Resistance 1 (R1) 74.81 74.73 74.94 74.82 75.13
Pivot Point 74.52 74.52 74.59 74.53 74.52
Support 1 (S1) 74.27 74.32 74.40 74.28 73.97
Support 2 (S2) 73.98 74.19 73.99 73.92
Support 3 (S3) 73.73 73.98 73.88
Support 4 (S4) 73.74